TL;DR: Sudden sensorineural hearing loss (SSNHL) is a medical emergency and a UHMS-approved indication for hyperbaric oxygen therapy. A 2025 meta-analysis of 20 studies found that HBOT combined with medical therapy gives patients 2.61 times higher odds of hearing recovery compared to steroids alone. Time is critical – referral within 14 days yields the best outcomes. Treatment is available at hospitals and regulated facilities across Canada.
Sudden sensorineural hearing loss (SSNHL) is a rapid, unexplained hearing deficit of 30 decibels or greater across three consecutive audiometric frequencies, occurring within 72 hours or less. It affects an estimated 5 to 27 per 100,000 people annually and is considered a medical emergency requiring prompt evaluation and treatment. For Canadian physicians, understanding when and how to refer patients for hyperbaric oxygen therapy (HBOT) can make the difference between permanent hearing loss and meaningful recovery.
This evidence-based referral guide from Canada Hyperbarics reviews the latest research, outlines patient selection criteria, and provides a practical referral pathway for physicians across the country. Estimated reading time: 9 minutes.
What Is Sudden Sensorineural Hearing Loss and Why Does It Require Urgent Referral?
SSNHL is a disorder of the inner ear or auditory nerve characterised by a rapid decline in hearing, typically unilateral. The condition is also called idiopathic sudden sensorineural hearing loss (ISSHL) when no identifiable cause is found, which accounts for approximately 90% of cases. The underlying mechanism is thought to involve cochlear ischaemia, viral inflammation, or autoimmune damage to the hair cells and stria vascularis.
Urgency matters because the window for effective treatment is narrow. Patients who begin treatment within the first 14 days of symptom onset have significantly better outcomes than those treated after 30 days. Without treatment, spontaneous recovery occurs in roughly 32% to 65% of cases, though recovery is often incomplete. The addition of HBOT to standard corticosteroid therapy has been shown to substantially improve these odds.
SSNHL is one of the 14 indications approved by the Undersea and Hyperbaric Medical Society (UHMS) for hyperbaric oxygen therapy, and it is recognised by Health Canada as a legitimate clinical application. The Canadian Undersea and Hyperbaric Medical Association (CUHMA) also endorses HBOT for this indication.
What Does the Current Evidence Say About HBOT for Sudden Hearing Loss?
The evidence base for HBOT in SSNHL has strengthened considerably in recent years. According to PubMed, multiple systematic reviews and meta-analyses published between 2022 and 2025 consistently show a significant benefit when HBOT is combined with corticosteroid therapy.
The largest and most recent meta-analysis (Alter et al., 2025) in The Laryngoscope analysed 20 studies including 16 randomised controlled trials (RCTs) involving 1,687 patients. Patients receiving HBOT combined with medical therapy had 2.61 times higher odds of hearing recovery compared to medical therapy alone (95% CI: 1.86-3.68, p < 0.001). Subgroup analysis showed the benefit held for both HBOT combined with systemic steroids alone (OR 2.54) and HBOT combined with systemic plus intratympanic steroids (OR 2.64) (DOI: 10.1002/lary.32472).
A notable Canadian contribution comes from Joshua et al. (2022) at the University of British Columbia, published in JAMA Otolaryngology – Head & Neck Surgery. Their systematic review of three prospective RCTs found a mean absolute hearing gain of 10.3 dB (95% CI: 6.5-14.1 dB) favouring HBOT, with an odds ratio of 4.3 for hearing recovery (95% CI: 1.6-11.7). Importantly, this analysis showed zero statistical heterogeneity (I² = 0%), lending high confidence to the pooled estimate (DOI: 10.1001/jamaoto.2021.2685).
An updated Cochrane-style systematic review by Newth et al. (2025) in Diving and Hyperbaric Medicine pooled data from seven randomised studies and found a relative risk of 1.6 for hearing improvement with HBOT plus steroids versus steroids alone, with a mean improvement of 15.6 dB (95% CI: 1.5-29.8). The authors concluded there is “moderate evidence that HBOT improves hearing when applied up to 30 days after onset” and that HBOT in combination with steroids “can be justified as a routine treatment” (DOI: 10.28920/dhm55.4.398-406).
Additional support comes from Moghib et al. (2025) in the European Archives of Oto-Rhino-Laryngology, who analysed 14 RCTs involving 794 participants and found significant improvement in low-frequency hearing thresholds (SMD: 0.83, p < 0.0001) and increased odds of complete recovery (OR: 2.05, 95% CI: 1.41-2.98) (DOI: 10.1007/s00405-025-09372-2).
Summary of Recent Meta-Analyses: HBOT for SSNHL
| Study | Year | Studies Included | Patients | Key Finding |
|---|---|---|---|---|
| Alter et al., Laryngoscope | 2025 | 20 (16 RCTs) | 1,687 | OR 2.61 for hearing recovery (p < 0.001) |
| Newth et al., Diving Hyperb Med | 2025 | 7 RCTs | N/R | RR 1.6; mean gain 15.6 dB |
| Moghib et al., Eur Arch Otorhinolaryngol | 2025 | 14 RCTs | 794 | OR 2.05 for complete recovery |
| Joshua et al., JAMA Otolaryngol (Canada) | 2022 | 3 RCTs | 150 | OR 4.3; mean gain 10.3 dB |
| Rhee et al., JAMA Otolaryngol | 2018 | 19 studies | 2,401 | OR 1.61 complete recovery; OR 1.43 any recovery |
Which Patients Are Most Likely to Benefit from Hyperbaric Oxygen Therapy?
Not every SSNHL patient will benefit equally from HBOT. The evidence points to several key factors that predict a better response to treatment.
Severity of hearing loss: Patients with severe to profound hearing loss (greater than 70 dB) at baseline show the greatest benefit from HBOT. Rhee et al. (2018) found that the advantage of adding HBOT was significantly greater in patients with initial hearing loss of 81 dB or more (DOI: 10.1001/jamaoto.2018.2133).
Timing of treatment: Earlier initiation is associated with better outcomes. The strongest evidence supports starting HBOT within the first 14 days of symptom onset. Newth et al. found moderate evidence of benefit when HBOT is applied within 30 days. Beyond this window, benefits diminish substantially.
Primary versus salvage therapy: HBOT can be used as part of initial combination therapy (with systemic steroids) or as salvage treatment for patients who do not respond to steroids alone. Both approaches show benefit. Lei et al. (2021) compared HBOT and intratympanic steroids as salvage therapies and found comparable efficacy (RR 1.09, 95% CI: 0.83-1.42), suggesting both are viable rescue options (DOI: 10.1097/MAO.0000000000003198).
Frequency-specific response: Moghib et al. (2025) found that HBOT combined with corticosteroids produced particularly significant improvements at low-frequency hearing thresholds, which may be relevant for physicians counselling patients about expected outcomes.
What Are the Contraindications Physicians Should Screen For?
Before referring a patient for HBOT, physicians should screen for the following contraindications to ensure patient safety.
Absolute contraindications:
- Untreated pneumothorax
- Active pulmonary blebs or bullae at high risk of rupture
- Concurrent use of doxorubicin, cisplatin, or disulfiram (risk of enhanced toxicity under hyperbaric conditions)
Relative contraindications requiring careful assessment:
- Uncontrolled seizure disorder
- Severe claustrophobia (particularly for monoplace chambers)
- Upper respiratory infection or sinusitis (barotrauma risk)
- Uncontrolled high fever
- Inability to equalise middle ear pressure
- Pregnancy (limited safety data)
- Congestive heart failure with ejection fraction below 35%
Across the meta-analyses reviewed, adverse events associated with HBOT for SSNHL were generally mild. The most commonly reported side effects include transient middle ear barotrauma, mild vertigo, and temporary myopia. Serious adverse events are rare when treatment is delivered at accredited facilities following established protocols. For a complete overview of approved conditions and screening considerations, visit the Canada Hyperbarics conditions resource.
What Does a Standard HBOT Protocol for SSNHL Look Like?
While treatment protocols vary between centres, the following parameters represent the most commonly used approach in the clinical literature.
Standard HBOT protocol for SSNHL:
- Pressure: 2.0 to 2.5 atmospheres absolute (ATA), with most centres using 2.0 to 2.4 ATA
- Duration: 60 to 90 minutes of oxygen breathing per session at treatment pressure
- Frequency: Once or twice daily, five to six days per week
- Total sessions: 10 to 20 sessions depending on clinical response
- Combination therapy: Administered alongside systemic corticosteroids (typically oral prednisone) and/or intratympanic steroid injections
The total treatment duration of at least 1,200 minutes (approximately 20 sessions at 60 minutes each) was associated with greater benefit in the Rhee et al. meta-analysis. Clinicians should monitor audiometric progress after the first 10 sessions to assess response and determine whether additional sessions are warranted.
How Do Canadian Physicians Refer Patients for Hyperbaric Oxygen Therapy?
The referral process for HBOT in Canada varies by province and by facility type. Here is a practical step-by-step pathway for referring physicians.
Step 1: Confirm the diagnosis. Document audiometric findings showing 30 dB or greater sensorineural hearing loss across three consecutive frequencies within 72 hours. Rule out conductive causes and retrocochlear pathology (consider MRI to exclude vestibular schwannoma).
Step 2: Initiate corticosteroid therapy. Begin systemic steroids immediately while arranging the HBOT referral. Do not delay steroid initiation while waiting for HBOT access.
Step 3: Locate an accredited hyperbaric facility. Use the Canada Hyperbarics facility directory to find hospitals and regulated facilities in your province. CUHMA maintains a list of accredited centres across the country.
Step 4: Communicate urgency. When contacting the hyperbaric facility, emphasise that SSNHL is a time-sensitive condition. Most hyperbaric centres are familiar with the urgency and can expedite intake for acute SSNHL referrals.
Step 5: Provide documentation. Include the audiogram, date of symptom onset, current medications (especially steroids), and relevant medical history including contraindication screening results.
Provincial Coverage Considerations
Coverage for HBOT varies across Canadian provinces. In Ontario, OHIP covers HBOT for approved indications at both hospital-based and eligible private clinics. In British Columbia, MSP covers treatment at Vancouver General Hospital, though private clinic treatment is not covered by MSP. In Alberta, AHCIP covers treatment at Alberta Health Services hospital clinics in Calgary and Edmonton. For a detailed province-by-province breakdown, visit the Canada Hyperbarics coverage guide.
For patients without provincial coverage, many private insurance plans cover HBOT for UHMS-approved indications, and some hyperbaric facilities offer direct billing arrangements.
Frequently Asked Questions About HBOT for Sudden Hearing Loss
How quickly should a patient be referred for HBOT after sudden hearing loss?
As soon as possible. The best evidence supports initiating HBOT within 14 days of symptom onset. Benefit has been demonstrated up to 30 days, but outcomes decline with each week of delay. Treat SSNHL referrals with the same urgency as other acute sensory emergencies.
Can HBOT be used as a standalone treatment for SSNHL?
The evidence most strongly supports HBOT as a combination therapy alongside systemic corticosteroids. While some studies have evaluated HBOT alone, the meta-analyses consistently show the greatest benefit when HBOT is added to standard steroid therapy rather than used as a replacement.
What is the success rate of HBOT for sudden hearing loss?
Success rates vary by definition and patient population. In the Alter et al. (2025) meta-analysis, patients receiving HBOT plus medical therapy had 2.61 times higher odds of hearing recovery. For patients with severe to profound loss, the benefit is even more pronounced. Complete recovery rates depend on initial severity, timing, and protocol adherence.
Is HBOT safe for elderly patients with SSNHL?
HBOT is generally well tolerated across age groups. The most common side effects are mild and self-limiting, including middle ear barotrauma and temporary myopia. Elderly patients should be screened carefully for cardiac and pulmonary contraindications, but age alone is not a contraindication to treatment.
Should I refer for HBOT if the patient has already started intratympanic steroids?
Yes. The Alter et al. meta-analysis found that HBOT provided significant additional benefit even when combined with both systemic and intratympanic steroids (OR: 2.64, 95% CI: 1.39-5.02). Intratympanic steroid therapy does not preclude or diminish the benefit of adding HBOT.
What if the nearest hyperbaric facility is far from my patient?
Given the time-sensitive nature of SSNHL, patients in rural or remote areas may need to travel to access HBOT. The Canada Hyperbarics facility directory can help identify the closest accredited centre. Some provinces have patient travel assistance programmes that may help cover transportation costs for medically necessary treatments.
How does HBOT compare to intratympanic steroids as salvage therapy?
A 2021 meta-analysis by Lei et al. found no significant difference in hearing outcomes between HBOT and intratympanic steroids as salvage therapies (RR 1.09, 95% CI: 0.83-1.42). Both offer comparable benefit for patients with refractory SSNHL. The combination of intratympanic steroids with HBOT may provide the strongest salvage response, though more research is needed.
Key Takeaways for Referring Physicians
The evidence is clear: adding HBOT to corticosteroid therapy for SSNHL significantly improves hearing outcomes. The data from five recent meta-analyses consistently favour combination therapy, with the strongest benefits seen in patients with severe to profound hearing loss who begin treatment within 14 days.
For Canadian physicians, the key clinical action points are:
- Recognise SSNHL as a medical emergency requiring same-day or next-day audiometric confirmation
- Start systemic corticosteroids immediately while arranging the HBOT referral
- Refer to an accredited hyperbaric facility within 14 days of symptom onset for optimal outcomes
- Screen for contraindications before referral to avoid delays at the hyperbaric centre
- Communicate the time-sensitive nature of the referral to the receiving facility
To find hospitals and regulated facilities offering HBOT in your province, visit the Canada Hyperbarics facility directory. For the latest research on hyperbaric medicine across all conditions, explore the Canada Hyperbarics research library, which catalogues over 11,000 peer-reviewed studies.
This content is for informational purposes only and does not constitute medical advice. Clinical decisions regarding HBOT referral should be made on an individual basis considering the patient’s complete medical history, audiometric findings, and available resources. Always consult current clinical guidelines and the treating hyperbaric physician when making referral decisions.